Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...

Drug discovery has long been criticized for its slow, costly, and failure-prone nature. Traditional approaches, particularly ...

With the rise of advanced simulation and model-informed drug development (MIDD) techniques like digital twins, researchers ...

In April 2025, the US Food and Drug Administration (FDA) published a roadmap for leveraging new approach methodologies (NAMs), including in silico approaches such as artificial intelligence (AI), to ...

In an industry where 90 percent of drug candidates fail before reaching the market, a handful of startups are betting ...

Overview of Nanotechnology Drug Delivery MarketThe global Nanotechnology Drug Delivery Market is valued at USD 97.98 Billion ...

At the Mount Sinai Health System we have successfully translated many algorithms from concept to testing and clinical care, in ways that have led to financial savings and improved patient outcomes.

The partnership between Avant Technologies Inc. and Ainnova Tech has created AAC (Ai-nova Acquisition Corp.), which holds worldwide licensing rights for Ainnova's entire technology portfolio. This ...

AI-generated papers are on the rise, and concerns grow around authorship, AI plagiarism, and maintaining trust in ...

Registered by the Federal Service for Supervision of Communications, Information Technology and Mass Communications.

Quantum computing is no longer a distant threat; it’s an imminent challenge that could break current cryptographic defenses. Many organizations are unprepared for this paradigm shift, risking severe ...

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, highlighting notable ocular toxicities and missed opportunities for dosing ...